NewAmsterdam Pharma Company NV Ordinary Shares

Yahoo Finance • 4 months ago

NewAmsterdam Pharma Second Quarter 2024 Earnings: Beats Expectations

NewAmsterdam Pharma (NASDAQ:NAMS) Second Quarter 2024 Results Key Financial Results Net loss: US$39.0m (loss widened by 1.9% from 2Q 2023). US$0.41 loss per share. earnings-and-revenue-growth All figures shown in the chart above are for... Full story

Yahoo Finance • 7 months ago

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

NewAmsterdam Pharma N.V. -- Enrolled over 9,500 patients in Phase 3 PREVAIL global CVOT-- -- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Dosed first... Full story

Yahoo Finance • 8 months ago

NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease

NewAmsterdam Pharma N.V Enrollment to continue to the end of April to accommodate strong patient and site interest NAARDEN, the Netherlands and MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “... Full story

Yahoo Finance • last year

Forbion co-leads €129 million Series A financing of VectorY, one of the largest private biotech financings in Europe in 2023

Round co-led by Forbion and EQT Life Sciences Financing will support clinical development of VTx-002, a potentially disease-modifying therapy for Amyotrophic Lateral Sclerosis (ALS) and additional pipeline programs Successful fundraising d... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights

-- BROADWAY Phase 3 trial enrollment completed; on-track to report topline data for Phase 3 BROOKLYN and BROADWAY trials in 2H 2024 – -- Announced initial data from Phase 2a clinical trial evaluating obicetrapib in patients with early Alz... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer

NAARDEN, the Netherlands and MIAMI, Oct. 23, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story

Yahoo Finance • last year

Tessellate BIO Emerges from Stealth

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populationsLead program targets Alternative Lengthening of Telomeres (ALT) through the FANCM prot... Full story

Yahoo Finance • last year

NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference

NAARDEN, The Netherlands and MIAMI, Sept. 20, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medi... Full story

Yahoo Finance • last year

NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer

NAARDEN, The Netherlands and MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines fo... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares

NAARDEN, The Netherlands and MIAMI, June 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a clinical-stage biopharmaceutical company developing oral, non-statin medicines for... Full story

Yahoo Finance • 2 years ago

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Dualyxraises €40 million to progress Treg therapies for autoimmune diseases into the clinic Use of proceeds will enable the development of the Company’s lead autoimmune program DT-001,targeting TNFR2, as well as its pipeline of Treg candi... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

-- Enrollment Completed Several Months Ahead of Schedule, Reflecting Significant Unmet Need and Patient Demand for New Options -- -- Topline Results Expected in 2H 2024 – NAARDEN, the Netherlands and MIAMI, April 24, 2023 (GLOBE NEWSWIR... Full story

Yahoo Finance • 2 years ago

Forbion raises €1.35 billion across two funds

Forbion’s largest fundraising to date€750 million raised in the final close of the Forbion Ventures Fund VI €600 million raised in the final close of the Forbion Growth Opportunities Fund II Brings the total of funds under management at Fo... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Appoints Janneke van der Kamp to its Board of Directors

NAARDEN, the Netherlands and MIAMI, April 03, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfo... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Reports Full Year 2022 Financial Results and Provides Corporate Update

-- Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 -- -- Announ... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma to Present at the SVB Securities Global BioPharma Conference

NAARDEN, the Netherlands and MIAMI, Feb. 09, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfor... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Pharma Appoints John W. Smither to its Board of Directors

NAARDEN, The Netherlands and MIAMI, Feb. 06, 2023 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam Pharma” or the “Company”), a clinical-stage company focused on the research and development of transfor... Full story

Yahoo Finance • 2 years ago

NewAmsterdam Announces Positive Results from ROSE2, Phase 2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy

-- Achieved primary endpoint with statistically significant reduction in LDL-C (p < 0.0001) -- -- Median percent change in LDL-C of -59% in combination arm compared to -6% in placebo arm -- -- Favorable safety and tolerability -- -- Data s... Full story